# Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Rheumatoid Arthritis

> **NCT02176876** · PHASE1 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 18 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** GS-5745
- **DRUG:** Placebo to match GS-5745

## Key facts

- **NCT ID:** NCT02176876
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2015-04
- **Final completion:** 2015-06
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2015-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02176876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02176876, "Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02176876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*